SYBX - Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023 | Benzinga
- Poster presentation on SYNB1353 program for homocystinuria includes findings from process improvements to improve activity of methionine degradation -
CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announced that an abstract outlining the SYNB1353 program as a potential treatment for homocystinuria (HCU), including findings from fermentation process improvements to increase activity of methionine degradation, has been accepted and will be presented at the International Conference on Microbiome Engineering 2023, held in Berkeley, California on December 8th to 10th.
Poster presentation details are as follows:
- Title: Improvements of SYNB1353, an Engineered Bacteria for the Treatment of Homocystinuria Lead to Increased In vitro and In vivo Degradation of Methionine
- Date: Saturday, December 9, 2023
- Session & Time: Poster Session B, 11:35 am – 12:45 pm PST
- Presenter: David Lubkowicz, Ph.D., Head, Strain Engineering & Characterization and HCU Program Lead at Synlogic
For more information, please visit the conference website. The poster will be available following the conference on the Synlogic website.
About Homocystinuria (HCU) & SYNB1353
HCU is a rare metabolic disease characterized by extreme levels of homocysteine and caused by an inherited deficiency in an enzyme known as cystathionine beta-synthase (CBS). When CBS is absent, homocysteine builds up in the blood and urine, putting patients at risk of multisystem complications, including acute thromboembolic events, optical damage from lens dislocation, skeletal deficiencies, and neurocognitive impairments. Methionine (Met), an essential amino acid in dietary protein, is a required precursor to homocysteine, and a restrictive, low-Met diet is a standard treatment for lowering ...